| 63.63 0.77 (1.22%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 79.35 |
1-year : | 92.68 |
| Resists | First : | 67.94 |
Second : | 79.35 |
| Pivot price | 63 |
|||
| Supports | First : | 62.55 |
Second : | 59.22 |
| MAs | MA(5) : | 63.55 |
MA(20) : | 63.27 |
| MA(100) : | 70.53 |
MA(250) : | 60.41 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 50.6 |
D(3) : | 51.2 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 80.27 | Low : | 40.45 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GKOS ] has closed below upper band by 40.1%. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 64.06 - 64.32 | 64.32 - 64.57 |
| Low: | 61.51 - 61.8 | 61.8 - 62.07 |
| Close: | 63.17 - 63.62 | 63.62 - 64.05 |
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Fri, 08 Dec 2023
Investors in Glaukos (NYSE:GKOS) have seen favorable returns of 38% over the past year - Simply Wall St
Thu, 07 Dec 2023
Glaukos (NYSE:GKOS) Lowered to "Sell" at StockNews.com - MarketBeat
Wed, 29 Nov 2023
Truist starts Glaukos at buy, cites glaucoma market opportunity (GKOS) - Seeking Alpha
Wed, 15 Nov 2023
Here's Why You Should Retain Glaukos (GKOS) Stock for Now - Yahoo Finance
Fri, 03 Nov 2023
What Is Glaukos Corporation's (NYSE:GKOS) Share Price Doing? - Yahoo Finance
Fri, 03 Nov 2023
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 49 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 101.1 (%) |
| Shares Short | 6,690 (K) |
| Shares Short P.Month | 6,120 (K) |
| EPS | -2.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.8 |
| Profit Margin | -42.7 % |
| Operating Margin | -35.9 % |
| Return on Assets (ttm) | -7.8 % |
| Return on Equity (ttm) | -25.3 % |
| Qtrly Rev. Growth | 9.5 % |
| Gross Profit (p.s.) | 4.38 |
| Sales Per Share | 6.22 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -23.66 |
| PEG Ratio | -3.7 |
| Price to Book value | 6.49 |
| Price to Sales | 10.22 |
| Price to Cash Flow | -60.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|